nach oben

Current Rheumatology Reports

Erschienen in:

01.10.2016 | Spondyloarthritis (MA Khan, Section Editor)

Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis

verfasst von: Tony J. Kenna, Aimee Hanson, Mary-Ellen Costello, Matthew A. Brown

Erschienen in: Current Rheumatology Reports | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Ankylosing spondylitis (AS) is a highly heritable disease for which there is a great unmet need for improved therapies. Genetics research has identified several major pathways involved in the disease, from which treatments have either now entered clinical practice or are in development. In particular, therapies targeting the IL-23 pathway were repositioned for use in AS following the discovery of multiple genes in the pathway as determinants of AS risk. Discovery of the association of aminopeptidase genes with AS, and subsequently with psoriasis, inflammatory bowel disease and other conditions, has triggered research into therapies targeting this pathway. The AS-genetic associations point to involvement of gut mucosal immunity in driving disease, and metagenomic studies have provided strong support that AS is a disease driven by interaction between the gut microbiome and host immune system, providing a rationale for the exploration of gut-targeted therapies for the disease.

Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis—insights into pathogenesis. Nat Rev Rheumatol. 2016;12(2):81–91. doi:10.1038/nrrheum.2015.133.CrossRefPubMed

2.••

Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48(5):510–8. doi:10.1038/ng.3528. Identifies over 50 new loci associated with AS and documents the sharing of genetic architecture between AS and IBD and psoriasis in particular.CrossRefPubMedPubMedCentral

Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43(8):761–7. doi:10.1038/ng.873.CrossRefPubMedPubMedCentral

4.••

International Genetics of Ankylosing Spondylitis C, Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7):730–8. doi:10.1038/ng.2667. More than doubled the total number of known AS loci and, amongst other things, confirmed associations of both ERAP2 and NPEPPS with AS, further strengthening evidence of the involvement of aminopeptidases and the disease.CrossRef

Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010;42(2):123–7. doi:10.1038/ng.513.CrossRefPubMedPubMedCentral

Danoy P, Pryce K, Hadler J, Bradbury LA, Farrar C, Pointon J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet. 2010;6(12):e1001195. doi:10.1371/journal.pgen.1001195.CrossRefPubMedPubMedCentral

7.••

Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun. 2015;6:7146. doi:10.1038/ncomms8146. Demonstrates association of multiple HLA alleles with AS, and epistasis between ERAP1 and HLA-B40 in AS, indicating that HLA-B40 and HLA-B27 probably act in similar ways to cause the condition.CrossRefPubMedPubMedCentral

Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet. 2013;14(9):661–73. doi:10.1038/nrg3502.CrossRefPubMed

Adolph TE, Tomczak MF, Niederreiter L, Ko HJ, Bock J, Martinez-Naves E, et al. Paneth cells as a site of origin for intestinal inflammation. Nature. 2013;503(7475):272–6. doi:10.1038/nature12599.PubMedPubMedCentral

10.

Wellcome Trust Case Control C, Australo-Anglo-American Spondylitis C, Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39(11):1329–37. doi:10.1038/ng.2007.17.CrossRef

11.

Chang SC, Momburg F, Bhutani N, Goldberg AL. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci U S A. 2005;102(47):17107–12. doi:10.1073/pnas.0500721102.CrossRefPubMedPubMedCentral

12.

Cui X, Rouhani FN, Hawari F, Levine SJ. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem. 2003;278(31):28677–85. doi:10.1074/jbc.M300456200.CrossRefPubMed

13.

Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol. 2003;171(12):6814–9. doi:10.4049/jimmunol.171.12.6814.CrossRefPubMed

14.

Cui X, Hawari F, Alsaaty S, Lawrence M, Combs CA, Geng W, et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Investig. 2002;110(4):515–26. doi:10.1172/jci0213847.CrossRefPubMedPubMedCentral

15.

Haroon N, Tsui FW, Chiu B, Tsui HW, Inman RD. Serum cytokine receptors in ankylosing spondylitis: relationship to inflammatory markers and endoplasmic reticulum aminopeptidase polymorphisms. J Rheumatol. 2010;37(9):1907–10. doi:10.3899/jrheum.100019.CrossRefPubMed

16.

Kochan G, Krojer T, Harvey D, Fischer R, Chen L, Vollmar M, et al. Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming. Proc Natl Acad Sci U S A. 2011;108(19):7745–50. doi:10.1073/pnas.1101262108.CrossRefPubMedPubMedCentral

17.

Goto Y, Hattori A, Ishii Y, Tsujimoto M. Reduced activity of the hypertension-associated Lys528Arg mutant of human adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase-1. FEBS Lett. 2006;580(7):1833–8. doi:10.1016/j.febslet.2006.02.041.CrossRefPubMed

18.•

Seregin SS, Rastall DP, Evnouchidou I, Aylsworth CF, Quiroga D, Kamal RP, et al. Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens. Autoimmunity. 2013;46(8):497–508. doi:10.3109/08916934.2013.819855. Evidence that ERAP1 variants influence HLA-B27 peptide presentation.CrossRefPubMedPubMedCentral

19.•

Sanz-Bravo A, Campos J, Mazariegos MS, Lopez de Castro JA. Dominant role of the ERAP1 polymorphism R528K in shaping the HLA-B27 peptidome through differential processing determined by multiple peptide residues. Arthritis Rheumatol. 2015;67(3):692–701. doi:10.1002/art.38980. Evidence that ERAP1 variants influence HLA-B27 peptide presentation.CrossRefPubMed

20.

Duchmann R, Lambert C, May E, Hohler T, Marker-Hermann E. CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clin Exp Immunol. 2001;123:315–22.CrossRefPubMedPubMedCentral

21.

Treviño MA, Teixeiro E, Bragado R. CD8+ T cells oligoclonally expanded in synovial fluid at onset of spondyloarthropathy selectively proliferate in response to self-antigens—characterization of cell specificities in nonclonal populations. J Rheumatol. 2004;31(10):1962–72.PubMed

22.

Frauendorf E, von Goessel H, May E, Marker-Hermann E. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clin Exp Immunol. 2003;134(2):351–9.CrossRefPubMedPubMedCentral

23.

Mamedov IZ, Britanova OV, Chkalina AV, Staroverov DB, Amosova AL, Mishin AS, et al. Individual characterization of stably expanded T cell clones in ankylosing spondylitis patients. Autoimmunity. 2009;42(6):525–36. doi:10.1080/08916930902960362.CrossRefPubMed

24.

Ruckert C, Fiorillo MT, Loll B, Moretti R, Biesiadka J, Saenger W, et al. Conformational dimorphism of self-peptides and molecular mimicry in a disease-associated HLA-B27 subtype. J Biol Chem. 2006;281(4):2306–16. doi:10.1074/jbc.M508528200.CrossRefPubMed

25.

Kaarela K, Jantti JK, Kotaniemi KM. Similarity between chronic reactive arthritis and ankylosing spondylitis. A 32-35-year follow-up study. Clin Exp Rheumatol. 2009;27(2):325–8.PubMed

26.

Virtala M, Kirveskari J, Granfors K. HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production. Infect Immun. 1997;65(10):4236–42.PubMedPubMedCentral

27.••

Chen L, Ridley A, Hammitzsch A, Al-Mossawi MH, Bunting H, Georgiadis D, et al. Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis. Ann Rheum Dis. 2016;75(5):916–23. doi:10.1136/annrheumdis-2014-206996. Links ERAP1 and KIR3DL2 with HLA-B27 in AS pathogenesis.CrossRefPubMed

28.

Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005;52(11):3586–95. doi:10.1002/art.21395.CrossRefPubMed

29.

Wong-Baeza I, Ridley A, Shaw J, Hatano H, Rysnik O, McHugh K, et al. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. J Immunol. 2013;190(7):3216–24. doi:10.4049/jimmunol.1202926.CrossRefPubMedPubMedCentral

30.••

Ridley A, Hatano H, Wong-Baeza I, Shaw J, Matthews KK, Al-Mossawi H, et al. Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA–B27 licenses pathogenic T cell differentiation in spondyloarthritis. Arthritis Rheumatol. 2016;68(4):901–14. doi:10.1002/art.39515/abstract. KIR3DL2 interaction with HLA-B27 linked to TH17 lymphocytes in AS.CrossRefPubMedPubMedCentral

31.

Harvey D, Pointon JJ, Evans DM, Karaderi T, Farrar C, Appleton LH, et al. Investigating the genetic association between ERAP1 and ankylosing spondylitis. Hum Mol Genet. 2009;18(21):4204–12. doi:10.1093/hmg/ddp371.CrossRefPubMedPubMedCentral

32.

Andres AM, Dennis MY, Kretzschmar WW, Cannons JL, Lee-Lin SQ, Hurle B, et al. Balancing selection maintains a form of ERAP2 that undergoes nonsense-mediated decay and affects antigen presentation. PLoS Genet. 2010;6(10):e1001157. doi:10.1371/journal.pgen.1001157.CrossRefPubMedPubMedCentral

33.••

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48. doi:10.1056/NEJMoa1505066. First anti-IL-17 biologic to show major activity in AS.CrossRefPubMed

34.•

Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23. doi:10.1136/annrheumdis-2013-204248. Preliminary data showing anti-IL-12p40 effective in AS.CrossRefPubMed

35.

Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009;60(4):955–65. doi:10.1002/art.24389.CrossRefPubMed

36.

Australo-Anglo-American Spondyloarthritis C, Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010;42(2):123–7. doi:10.1038/ng.513.CrossRef

37.

Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011;6(2):e17160. doi:10.1371/journal.pone.0017160.CrossRefPubMedPubMedCentral

38.

Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci U S A. 2011;108(23):9560–5. doi:10.1073/pnas.1017854108.CrossRefPubMedPubMedCentral

39.••

Di Meglio P, Villanova F, Napolitano L, Tosi I, Terranova Barberio M, Mak RK, et al. The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol. 2013;133(10):2381–9. doi:10.1038/jid.2013.170. Demonstrated that risk variants of IL23R increase IL-23 responsiveness.CrossRefPubMedPubMedCentral

40.

Awasthi A, Riol-Blanco L, Jager A, Korn T, Pot C, Galileos G, et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol. 2009;182(10):5904–8. doi:10.4049/jimmunol.0900732.CrossRefPubMedPubMedCentral

41.

Kenna TJ, Brown MA. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol. 2013;9(6):375–9. doi:10.1038/nrrheum.2012.205.CrossRefPubMed

42.

Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7(4):e31000. doi:10.1371/journal.pone.0031000.CrossRefPubMedPubMedCentral

43.

Ciccia F, Accardo-Palumbo A, Alessandro R, Rizzo A, Principe S, Peralta S, et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum. 2012;64(6):1869–78. doi:10.1002/art.34355.CrossRefPubMed

44.

Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat + CD3 + CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–76. doi:10.1038/nm.2817.CrossRefPubMed

45.

Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203(11):2473–83. doi:10.1084/jem.20061099.CrossRefPubMedPubMedCentral

46.•

Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, et al. Interleukin-23 mediates the intestinal response to microbial beta-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66(7):1755–67. doi:10.1002/art.38638. Demonstration of IL-23 dependence of mouse model of spondyloarthritis.CrossRefPubMed

47.

Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9. doi:10.1056/NEJMoa1109997.CrossRefPubMed

48.

Stebbings S, Munro K, Simon M, Tannock G, Highton J, Harmsen H, et al. Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology. 2002;41:1395–401.CrossRefPubMed

49.

Stone MA, Payne U, Schentag C, Rahman P, Pacheco-Tena C, Inman RD. Comparative immune responses to candidate arthritogenic bacteria do not confirm a dominant role for Klebsiella pneumonia in the pathogenesis of familial ankylosing spondylitis. Rheumatology. 2004;43(2):148–55. doi:10.1093/rheumatology/keg482.CrossRefPubMed

50.

Ebringer RW, Cawdell DR, Cowling P, Ebringer A. Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease. Ann Rheum Dis. 1978;37(2):146–51. doi:10.1136/ard.37.2.146.CrossRefPubMedPubMedCentral

51.

Ebringer A. The cross-tolerance hypothesis, HLA-B27 and ankylosing spondylitis. Rheumatology. 1983;XXII suppl 2:53–66. doi:10.1093/rheumatology/XXII.suppl_2.53.CrossRef

52.

O’Mahony S, Anderson N, Nuki G, Ferguson A. Systemic and mucosal antibodies to Klebsiella in patients with ankylosing spondylitis and Crohn’s disease. Ann Rheum Dis. 1992;51(12):1296–300. doi:10.1136/ard.51.12.1296.CrossRefPubMedPubMedCentral

53.

Mäki-ikola O, Nissilä M, Lehtinen K, Leirisalo-repo M, Toivanen P, Granfors K. Antibodies to Klebsiella pneumoniae, Eschericha coli and Proteus mirabilisin the sera of patients with axial and peripheral form of ankylosing spondylitis. Rheumatology. 1995;34(5):413–7. doi:10.1093/rheumatology/34.5.413.CrossRef

54.

Rosenbaum JT, Davey MP. Time for a gut check: evidence for the hypothesis that HLA–B27 predisposes to ankylosing spondylitis by altering the microbiome. Arthritis Rheum. 2011;63(11):3195–8. doi:10.1002/art.30558.CrossRefPubMedPubMedCentral

55.••

Costello M-E, Ciccia F, Willner D, Warrington N, Robinson PC, Gardiner B, et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol. 2015;67(3):686–91. doi:10.1002/art.38967. First demonstration that the gut microbiome of AS patients is distinct from healthy controls.CrossRef

56.

Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, et al. HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. PLoS ONE. 2014;9(8):e105684. doi:10.1371/journal.pone.0105684.CrossRefPubMedPubMedCentral

57.

van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15. doi:10.1056/NEJMoa1205037.CrossRefPubMed

58.

Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–8. http://www.nature.com/ajg/journal/v108/n4/suppinfo/ajg201359s1.html.CrossRefPubMed

59.

Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515–22. doi:10.1093/cid/ciu135.CrossRefPubMedPubMedCentral

60.

van Nood E, Speelman P, Nieuwdorp M, Keller J. Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroenterol. 2014;30(1):34–9. doi:10.1097/MOG.0000000000000024.CrossRefPubMed

61.

Smith M, Kassam Z, Edelstein C, Burgess J, Alm E. OpenBiome remains open to serve the medical community. Nat Biotech. 2014;32(9):867. doi:10.1038/nbt.3006.CrossRef

62.

Edelstein CA, Kassam Z, Daw J, Smith MB, Kelly CR. The regulation of fecal microbiota for transplantation: an international perspective for policy and public health. Clin Res Regul Aff. 2015;32(3):99–107. doi:10.3109/10601333.2015.1046602.CrossRef

63.

Consortium HMP. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14. http://www.nature.com/nature/journal/v486/n7402/abs/nature11234.html#supplementary-information.CrossRef

64.

Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infectious Diseases. 2015;2(1). doi:10.1093/ofid/ofv004.

65.

Petrof E, Gloor G, Vanner S, Weese S, Carter D, Daigneault M, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013;1(1):1–12. doi:10.1186/2049-2618-1-3.CrossRef

66.

Sachs RE, Edelstein CA. Ensuring the safe and effective FDA regulation of fecal microbiota transplantation. J Law Biosciences. 2015. doi:10.1093/jlb/lsv032.

67.

Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 2012;8(10):e1002995. doi:10.1371/journal.ppat.1002995.CrossRefPubMedPubMedCentral

68.

Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, et al. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med. 2015;13(1):1–12. doi:10.1186/s12967-015-0646-2.CrossRef

69.

Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility and efficacy trial results. J Gastroenterol Hepatol. 2014:n/a-n/a. doi:10.1111/jgh.12727.

70.

Blekhman R, Goodrich JK, Huang K, Sun Q, Bukowski R, Bell JT, et al. Host genetic variation impacts microbiome composition across human body sites. Genome Biol. 2015;16(1):191. doi:10.1186/s13059-015-0759-1.CrossRefPubMedPubMedCentral

71.••

Goodrich Julia K, Waters Jillian L, Poole Angela C, Sutter Jessica L, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell. 2014;159(4):789–99. doi:10.1016/j.cell.2014.09.053 . Demonstration that the gut microbiome composition is influenced by the host genome.

72.

Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Micro. 2011;9(4):279–90. http://www.nature.com/nrmicro/journal/v9/n4/suppinfo/nrmicro2540_S1.html.CrossRef

73.

Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci. 2010;107(44):18933–8. doi:10.1073/pnas.1007028107.CrossRefPubMedPubMedCentral

Titel: Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis
verfasst von: Tony J. Kenna
Aimee Hanson
Mary-Ellen Costello
Matthew A. Brown
Publikationsdatum: 01.10.2016
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 10/2016
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-016-0612-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2016

Gout and Osteoarthritis: Associations, Pathophysiology, and Therapeutic Implications

Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies

The Microbiome: a Revolution in Treatment for Rheumatic Diseases?

AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Update Innere Medizin